FDC Limited

Equities

FDC

INE258B01022

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:50 2024-04-19 am EDT 5-day change 1st Jan Change
448.6 INR -0.71% Intraday chart for FDC Limited -0.38% +13.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
FDC Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
FDC Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Tranche Update on FDC Limited's Equity Buyback Plan announced on August 9, 2023. CI
Carrefour sticks price warnings on food to shame suppliers RE
FDC Limited's Equity Buyback announced on August 9, 2023, has closed with 3,100,000 shares, representing 1.87% for INR 1,550 million. CI
FDC Limited announces an Equity Buyback for 3,100,000 shares, representing 1.87% for INR 1,550 million. CI
FDC Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
FDC Limited agreed to acquire remaining 7% stake in Fair Deal Corporation Pharmaceutical SA Ltd. from other existing shareholders. CI
FDC Limited authorizes a Buyback Plan. CI
FDC Board to Consider Buyback of Shares MT
FDC Limited's Board intends to launch an Equity Buyback on August 9, 2023 CI
FDC Limited's Board intends to launch an Equity Buyback on August 9, 2023. CI
FDC Gets Establishment Inspection Report from US FDA for Raigad, India Manufacturing Unit MT
FDC Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
FDC Names New CFO MT
FDC Limited Appoints Executive Changes CI
FDC's Consolidated Profit Climbs in Fiscal Q3 MT
FDC Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
FDC's Consolidated Profit Drops in Fiscal Q2 MT
FDC Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
FDC Limited Approves Appointment of Vijay S. Maniar as an Non-Executive and Independent Director CI
FDC Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
FDC Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022 CI
Tranche Update on FDC Limited's Equity Buyback Plan announced on February 9, 2022. CI
Tranche Update on FDC Limited's Equity Buyback Plan announced on February 9, 2022. CI
Chart FDC Limited
More charts
FDC Limited is an India-based company, which is principally engaged in the business of pharmaceuticals. The Company manufactures and distributes its range of generics, formulations, and active pharmaceuticals at its manufacturing plants. It also manufactures oral rehydration salts (ORS) and specialized formulations. It has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. It has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. FDC Stock
  4. News FDC Limited
  5. FDC's Consolidated Profit Drops in Fiscal Q2